<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Second and later lines of therapy for metastatic soft tissue sarcoma
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Second and later lines of therapy for metastatic soft tissue sarcoma
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Second and later lines of therapy for metastatic soft tissue sarcoma
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Suzanne George, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albiruni Abdul Razak, MD, MRCPI
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert Maki, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melinda Yushak, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 27, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1531832444">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Soft tissue sarcomas (STS) are a heterogeneous group of rare tumors that arise from mesenchymal cells, such as muscle, adipose, fibrous, cartilage, nerve, and vascular tissue. STS arise most frequently in the limbs (particularly the lower extremity), followed by the abdominal cavity/retroperitoneum, the trunk/thoracic region, and the head and neck. There are many histologic subtypes of STS which have distinct clinical profiles, molecular alterations, treatment responses, and prognoses. (See
         <a class="medical medical_review" href="/z/d/html/14259.html" rel="external">
          "Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma"
         </a>
         .)
        </p>
        <p>
         Second- and later-line therapies for common metastatic STS histologies that will be reviewed here. For most patients, we offer clinical trials specific to their histologic subtype, where available. For those who decline or are ineligible for clinical trials, our treatment approach is based on the specific STS histology and treatments previously received.
        </p>
        <p>
         An overview of the initial treatment of common advanced or metastatic STS histologies, the management of other types of advanced or metastatic STS (as noted below), bone sarcomas (Ewing sarcoma, osteosarcoma, chondrosarcoma), tenosynovial giant cell tumors, and select uncommon sarcoma subtypes are presented separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Overview of the initial treatment of metastatic soft tissue sarcoma (see
         <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">
          "Overview of the initial treatment of metastatic soft tissue sarcoma"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal stromal tumors (see
         <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">
          "Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Breast sarcoma (see
         <a class="medical medical_review" href="/z/d/html/83132.html" rel="external">
          "Breast sarcoma: Treatment"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Uterine leiomyosarcoma (see
         <a class="medical medical_review" href="/z/d/html/3188.html" rel="external">
          "Treatment and prognosis of uterine leiomyosarcoma"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Head and neck sarcomas (see
         <a class="medical medical_review" href="/z/d/html/3367.html" rel="external">
          "Head and neck sarcomas"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rhabdomyosarcoma (see
         <a class="medical medical_review" href="/z/d/html/7721.html" rel="external">
          "Rhabdomyosarcoma in childhood, adolescence, and adulthood: Treatment"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Desmoid tumors (see
         <a class="medical medical_review" href="/z/d/html/7749.html" rel="external">
          "Desmoid tumors: Systemic therapy"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Solitary fibrous tumors (see
         <a class="medical medical_review" href="/z/d/html/88706.html" rel="external">
          "Solitary fibrous tumor"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dermatofibrosarcoma protuberans (see
         <a class="medical medical_review" href="/z/d/html/89222.html" rel="external">
          "Dermatofibrosarcoma protuberans: Treatment"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kaposi sarcoma (see
         <a class="medical medical_review" href="/z/d/html/7729.html" rel="external">
          "Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8034.html" rel="external">
          "AIDS-related Kaposi sarcoma: Staging and treatment"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ewing sarcoma (see
         <a class="medical medical_review" href="/z/d/html/7740.html" rel="external">
          "Treatment of Ewing sarcoma"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Osteosarcoma (see
         <a class="medical medical_review" href="/z/d/html/7723.html" rel="external">
          "Chemotherapy and radiation therapy in the management of osteosarcoma"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chondrosarcoma (see
         <a class="medical medical_review" href="/z/d/html/7724.html" rel="external">
          "Chondrosarcoma"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tenosynovial giant cell tumors (see
         <a class="medical medical_review" href="/z/d/html/7733.html" rel="external">
          "Treatment for tenosynovial giant cell tumor and other benign neoplasms affecting soft tissue and bone", section on 'Tenosynovial giant cell tumor'
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Uncommon sarcoma subtypes (see
         <a class="medical medical_review" href="/z/d/html/114329.html" rel="external">
          "Uncommon sarcoma subtypes"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H520666073">
         <span class="h1">
          ANGIOSARCOMA
         </span>
        </p>
        <p class="headingAnchor" id="H196903236">
         <span class="h2">
          Second-line therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anthracycline-based regimens and taxanes are both used as initial therapy for most patients with metastatic angiosarcoma [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">
          "Overview of the initial treatment of metastatic soft tissue sarcoma", section on 'Angiosarcoma'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prior anthracyclines
         </strong>
         — For patients with metastatic angiosarcoma who progress on initial anthracycline-based therapy, we suggest second-line therapy with a taxane (such as
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         (
         <a class="graphic graphic_table graphicRef95037" href="/z/d/graphic/95037.html" rel="external">
          table 1
         </a>
         )) rather than other systemic agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          Paclitaxel
         </a>
         was evaluated in a single-arm phase II trial (ANGIOTAX) of 30 patients with unresectable angiosarcoma. At median follow-up of eight months, within the subgroup of 11 patients who had progressed on anthracycline-based chemotherapy, the progression-free survival (PFS) rate was 77 percent [
         <a href="#rid2">
          2
         </a>
         ]. Data for the entire study population, including chemotherapy-naïve patients, is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">
          "Overview of the initial treatment of metastatic soft tissue sarcoma", section on 'Angiosarcoma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prior taxanes
         </strong>
         — For patents with metastatic angiosarcoma who progress on taxanes, we suggest second-line therapy with an anthracycline-based regimen rather than other systemic agents. The rationale for anthracyclines as second-line therapy is mainly extrapolated from data on these agents as initial therapy for metastatic angiosarcoma that suggest similar efficacy to taxanes [
         <a href="#rid3">
          3-5
         </a>
         ]. Although clinical practice is variable and many anthracycline-based regimens are available, we use
         <a class="drug drug_general" data-topicid="10135" href="/z/d/drug information/10135.html" rel="external">
          pegylated liposomal doxorubicin
         </a>
         which is relatively well tolerated and effective in angiosarcomas previously treated with taxanes [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3336013418">
         <span class="h2">
          Later-line therapy (angiosarcoma)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Later-line options for metastatic angiosarcoma include gemcitabine-based regimens,
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         , and immune checkpoint inhibitors (ie, immunotherapy) such as
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         or
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         . Immunotherapy is especially effective for those with cutaneous or head and neck angiosarcomas.
        </p>
        <p class="headingAnchor" id="H720024490">
         <span class="h3">
          Gemcitabine-based regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gemcitabine-based regimens used as later-line therapy for angiosarcomas are the same as those used as initial therapy for select anthracycline-responsive metastatic STS histologies and are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">
          "Overview of the initial treatment of metastatic soft tissue sarcoma", section on 'Ineligible for anthracyclines'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2261476869">
         <span class="h3">
          Pazopanib (angiosarcoma)
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          Pazopanib
         </a>
         has activity as later-line therapy in patients with angiosarcoma, including those with cutaneous disease [
         <a href="#rid6">
          6-8
         </a>
         ]. Pazopanib improved PFS in a randomized placebo-controlled phase III trial (PALETTE) of patients with metastatic soft tissue sarcoma who had previously received chemotherapy (including anthracyclines) [
         <a href="#rid6">
          6
         </a>
         ]. Although this study presumably included patients with angiosarcoma, the specific number is unreported. (See
         <a class="local">
          'Pazopanib'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          Pazopanib
         </a>
         was also evaluated as the control therapy in a separate randomized study of 123 patients with treatment-refractory advanced angiosarcoma. Among the 64 patients with cutaneous angiosarcoma treated with pazopanib alone, median PFS and overall survival (OS) were six and eight months, respectively [
         <a href="#rid8">
          8
         </a>
         ]. However, for cutaneous angiosarcoma, it is challenging to accurately measure objective responses to pazopanib. For example, clinical benefit could present as a change in color and appearance rather a decrease in tumor size, whereas disease progression could present as tumor thickening and bleeding rather than an increase in tumor size.
        </p>
        <p class="headingAnchor" id="H881057105">
         <span class="h3">
          Pembrolizumab (angiosarcoma)
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          Pembrolizumab
         </a>
         , an immune checkpoint inhibitor, is a later-line treatment option for patients with angiosarcoma, especially those with cutaneous disease or tumors involving the head and neck region. In one case series, seven patients with angiosarcoma (five of whom had cutaneous angiosarcoma) were treated with immune checkpoint inhibitors, included four patients treated with pembrolizumab [
         <a href="#rid9">
          9
         </a>
         ]. At three-month follow-up, partial responses were seen in five patients (71 percent) either on imaging or clinical exam [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3367.html" rel="external">
          "Head and neck sarcomas", section on 'Angiosarcoma'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3358519774">
         <span class="h3">
          Nivolumab plus ipilimumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         Combination immunotherapy with
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         is an option for patients with previously treated angiosarcoma, especially those with cutaneous disease or tumors involving the head and neck region. Nivolumab plus ipilimumab was evaluated in a single-arm phase II trial of 16 patients with unresectable angiosarcoma, including nine patients with cutaneous disease [
         <a href="#rid10">
          10
         </a>
         ]. Objective responses were seen in four patients (25 percent) and complete responses were seen in three of five patients with cutaneous scalp or face tumors (60 percent). The six-month PFS was 38 percent.
        </p>
        <p class="headingAnchor" id="H463314432">
         <span class="h3">
          Other agents (angiosarcoma)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other agents with modest clinical activity (objective response rates of less than 20 percent) include
         <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">
          vinorelbine
         </a>
         [
         <a href="#rid11">
          11
         </a>
         ],
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         [
         <a href="#rid12">
          12
         </a>
         ],
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         [
         <a href="#rid13">
          13,14
         </a>
         ],
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         [
         <a href="#rid15">
          15
         </a>
         ], and
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         [
         <a href="#rid16">
          16,17
         </a>
         ]. There is no role for the addition of bevacizumab to
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         , which failed to improve OS in a randomized phase II trial of advanced angiosarcoma (ANGIOTAX-PLUS) [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H513578797">
         <span class="h1">
          LEIOMYOSARCOMA
         </span>
        </p>
        <p class="headingAnchor" id="H825639675">
         <span class="h2">
          Second-line therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with metastatic leiomyosarcoma (LMS), either anthracycline-based regimens or
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         are appropriate options for initial therapy. (See
         <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">
          "Overview of the initial treatment of metastatic soft tissue sarcoma", section on 'Leiomyosarcoma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3188.html" rel="external">
          "Treatment and prognosis of uterine leiomyosarcoma", section on 'Metastatic disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1349445608">
         <span class="h3">
          Gemcitabine plus docetaxel (LMS)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with metastatic LMS who progress on initial therapy with anthracycline-based regimens, we suggest second-line therapy with
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         (
         <a class="graphic graphic_table graphicRef58713" href="/z/d/graphic/58713.html" rel="external">
          table 2
         </a>
         ) rather than other gemcitabine-based regimens. Studies also suggest that this combination has specific activity in treatment-refractory LMS.
        </p>
        <p>
         For those who are unable to tolerate the potential toxicities of adding
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         to
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         , appropriate alternatives include other gemcitabine-based combinations (gemcitabine plus
         <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">
          vinorelbine
         </a>
         , gemcitabine plus
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         ) and single-agent gemcitabine, extrapolating from studies of these agents as initial systemic therapy. Single-agent gemcitabine is favored in patients with limited disease burden without impending organ dysfunction, older adults, or those with significant comorbidities. (See
         <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">
          "Overview of the initial treatment of metastatic soft tissue sarcoma", section on 'Ineligible for anthracyclines'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          Gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         is an active agent in anthracycline-refractory LMS [
         <a href="#rid19">
          19-24
         </a>
         ] that can stabilize disease in a majority of patients [
         <a href="#rid25">
          25
         </a>
         ], although data are mixed for its efficacy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective analysis, 133 patients with unresectable or metastatic STS (a majority of whom had previously received
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         and/or
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         ) were treated with
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         . The study included 76 patients with leiomyosarcoma and 57 patients with other histologic subtypes. Among patients with leiomyosarcoma, gemcitabine plus docetaxel demonstrated objective response rate of 24 percent and one-year overall survival (OS) of 56 percent [
         <a href="#rid19">
          19
         </a>
         ]. Among patients receiving this combination, LMS was associated with improved OS compared with other histologies, which has also been confirmed in other studies [
         <a href="#rid20">
          20,22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         By contrast, in a randomized phase II trial (TAXOGEM), the addition of
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         to
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         failed to improve outcomes in patients with anthracycline-refractory nonuterine LMS. However, this regimen stabilized disease in over half of patients.
        </p>
        <p>
        </p>
        <p>
         In the TAXOGEM study, 90 patients with metastatic LMS of uterine (n = 46) or nonuterine (n = 44) origin who had previously received one prior anthracycline-based regimen were randomly assigned to either
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         (900 mg/m
         <sup>
          2
         </sup>
         on days 1 and 8) plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         (100 mg/m
         <sup>
          2
         </sup>
         on day 8 of a 21-day cycle) or gemcitabine alone (1000 mg/m
         <sup>
          2
         </sup>
         on
         <sup>
         </sup>
         days 1, 8, and 15 of a 28-day cycle) [
         <a href="#rid25">
          25
         </a>
         ]. Among those with nonuterine LMS, the addition of docetaxel to gemcitabine demonstrated lower objective response rates (5 versus 14 percent) and failed to improve progression-free survival (PFS; median 3.8 versus 6.3 months). However, the stable disease rate was similar between the two treatment arms (58 versus 53 percent).
        </p>
        <p class="headingAnchor" id="H4278033658">
         <span class="h3">
          Anthracycline-based regimens (LMS)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with metastatic leiomyosarcoma (LMS) who progress on initial therapy with
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         , we suggest second-line therapy with an anthracycline-based regimen rather than other systemic agents, extrapolating from studies of these agents as initial systemic therapy. Effective regimens include
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         plus
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         and doxorubicin plus
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         , which are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">
          "Overview of the initial treatment of metastatic soft tissue sarcoma", section on 'Leiomyosarcoma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2648541919">
         <span class="h2">
          Later-line therapy (LMS)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The selection of later-line therapy for metastatic leiomyosarcoma (LMS) is based on patient co-morbidities and performance status as well as patient and clinician preference. Options (if not previously received), include
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         ,
         <a class="drug drug_general" data-topicid="16096" href="/z/d/drug information/16096.html" rel="external">
          eribulin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         , among other agents.
        </p>
        <p class="headingAnchor" id="H1526127495">
         <span class="h3">
          Trabectedin (LMS)
         </span>
        </p>
        <p class="headingAnchor" id="H2433149330">
         <span class="h4">
          Dosing and administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          Trabectedin
         </a>
         is an antineoplastic agent that kills cells by poisoning the DNA nucleotide excision repair machinery [
         <a href="#rid26">
          26
         </a>
         ]. Trabectedin was originally isolated from the Caribbean sea sponge
         <em>
          Ecteinascidia turbinata
         </em>
         , but it is now synthetically produced.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          Trabectedin
         </a>
         is administered at 1.5 mg/m
         <sup>
          2
         </sup>
         intravenously over 24 hours on day 1 of a 21-day cycle.
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         (20 mg) is administered intravenously 30 minutes prior to each dose to reduce hepatotoxicity risk [
         <a href="#rid27">
          27,28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2837.html" rel="external">
          "Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Conventional cytotoxic agents", section on 'Trabectedin'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          Trabectedin
         </a>
         is administered on an every-three-week schedule because this approach prolonged treatment response over weekly dosing in a randomized phase II trial of patients with previously treated advanced leiomyosarcoma (LMS) or liposarcoma. In this study, administering trabectedin at 1.5 mg/m
         <sup>
          2
         </sup>
         intravenously on day 1 of a 21-day cycle improved the median time to tumor progression compared with 0.58 mg/m
         <sup>
          2
         </sup>
         intravenously on days 1, 8, and 15 of a 28-day cycle (3.7 versus 2.3 months, hazard ratio [HR] 0.73, 95% CI 0.55-0.97) [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2901076325">
         <span class="h4">
          Efficacy and toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          Trabectedin
         </a>
         improved PFS and had similar OS compared with
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         in a phase III trial of patients with treatment-refractory leiomyosarcoma [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p>
         The efficacy of
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         in LMS was initially established in phase II trials of both chemotherapy-naïve and refractory LMS [
         <a href="#rid32">
          32-36
         </a>
         ]. In a subsequent phase III trial (ET743-SAR-3007), 577 patients with advanced LMS or liposarcoma previously treated with anthracycline-based chemotherapy were randomly assigned to trabectedin versus
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         [
         <a href="#rid30">
          30,31
         </a>
         ]. Most of the patients with LMS had received both doxorubicin-based and gemcitabine-based therapy. Approximately three-fourths of those enrolled had LMS (423 patients), and the remaining one-third had liposarcomas (154 patients).
        </p>
        <p>
         At median follow-up of approximately 21 months,
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         resulted in the following, relative to
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         [
         <a href="#rid30">
          30,31
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Entire study population
         </strong>
         – Improved PFS (median 4 versus 2 months, HR 0.55, 95% CI 0.44-0.70) and similar overall survival (OS; median 14 versus 13 months, HR 0.93, 95% CI 0.75-1.15).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pretreated LMS
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Improved PFS and similar OS (median PFS 4 versus 2 months, HR 0.56, 95% CI 0.42-0.73; median OS 14 versus 13 months, HR 0.89, 95% CI 0.69-1.15).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Improved PFS in both nonuterine and uterine disease (nonuterine disease, median five versus two months, HR 0.58, 95% CI 0.37-0.92; uterine disease, four versus two months, HR 0.58, 95% CI 0.41-0.81).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Improved clinical benefit rates (ie, objective disease response plus stable disease rate; 37 versus 20 percent). Although the objective response rate for
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         by conventional criteria is low [
         <a href="#rid32">
          32-34,37,38
         </a>
         ], stable disease is also a beneficial endpoint for metastatic STS [
         <a href="#rid29">
          29,32-34,37,39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">
          "Overview of the initial treatment of metastatic soft tissue sarcoma", section on 'Assessment of treatment response'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Grade ≥3 toxicities for
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         included neutropenia, thrombocytopenia, anemia, and transient elevations in aminotransferases. Nine treatment-related deaths were reported due to infection, rhabdomyolysis, and renal failure. Trabectedin carries a warning for risk of severe and fatal neutropenic sepsis; rhabdomyolysis and hepatotoxicity; skin and soft tissue necrosis following extravasation; and heart failure. (See
         <a class="medical medical_review" href="/z/d/html/16414.html" rel="external">
          "Rhabdomyolysis: Epidemiology and etiology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2812.html" rel="external">
          "Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines", section on 'Trabectedin'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2797.html" rel="external">
          "Extravasation injury from cytotoxic and other noncytotoxic vesicants in adults", section on 'Selective use of antidotes'
         </a>
         .)
        </p>
        <p>
         Based on these data,
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         was approved by the US Food and Drug Administration (FDA) for patients with unresectable or metastatic LMS or liposarcoma who have received a prior anthracycline-containing therapy [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3614301520">
         <span class="h3">
          Pazopanib (LMS)
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          Pazopanib
         </a>
         is an option for patients with leiomyosarcoma (LMS) who progress on prior chemotherapy, including but not limited to anthracycline-based regimens. In a randomized, double-blind, placebo-controlled phase III trial (PALETTE), pazopanib demonstrated a non-statistically significant trend towards improved PFS in a subgroup of patients with anthracycline-refractory leiomyosarcoma (HR 0.88, 95% CI 0.63-1.21) [
         <a href="#rid6">
          6
         </a>
         ]. Data on pazopanib for the entire study population are discussed separately. (See
         <a class="local">
          'Efficacy and toxicity'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4194703231">
         <span class="h3">
          Eribulin (LMS)
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="16096" href="/z/d/drug information/16096.html" rel="external">
          Eribulin
         </a>
         is an option for treatment-refractory LMS. A randomized phase III trial compared eribulin to
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         in 452 patients with advanced LMS or liposarcoma previously treated with an anthracycline [
         <a href="#rid41">
          41-43
         </a>
         ]. Among the subgroup of 309 patients with leiomyosarcoma, eribulin demonstrated similar PFS (2.2 versus 2.6 months, HR 1.07, 95% CI 0.84-1.38), OS (median 12.7 versus 13 month; HR 0.93, 95% CI 0.71-1.20), and objective response rate (5 versus 7 percent) compared with dacarbazine [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Further details on the efficacy of
         <a class="drug drug_general" data-topicid="16096" href="/z/d/drug information/16096.html" rel="external">
          eribulin
         </a>
         in this study for liposarcoma are discussed separately. (See
         <a class="local">
          'Eribulin (liposarcoma)'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H153344751">
         <span class="h3">
          Dacarbazine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          Dacarbazine
         </a>
         is an option for treatment-refractory LMS. In separate randomized trials of patients with LMS who had progressed on prior chemotherapy including anthracyclines, dacarbazine demonstrated similar OS compared with
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         [
         <a href="#rid30">
          30,31
         </a>
         ] and
         <a class="drug drug_general" data-topicid="16096" href="/z/d/drug information/16096.html" rel="external">
          eribulin
         </a>
         [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1859007797">
         <span class="h3">
          Other agents (LMS)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other agents with modest activity in treatment-refractory LMS include
         <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">
          temozolomide
         </a>
         [
         <a href="#rid44">
          44,45
         </a>
         ], and
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         We do not routinely use the combination of
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         plus
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         to treat LMS. The addition of gemcitabine to pazopanib improved PFS rates in a randomized phase II trial of patients with soft tissue sarcoma (predominantly LMS and liposarcoma) who had progressed on prior anthracycline and/or ifosfamide-based therapy [
         <a href="#rid47">
          47
         </a>
         ] and had similar efficacy compared with gemcitabine plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         in a separate phase II trial [
         <a href="#rid20">
          20
         </a>
         ]. However, further data are necessary before incorporating this combination into routine clinical practice.
         <strong>
         </strong>
        </p>
        <p class="headingAnchor" id="H3833235364">
         <span class="h1">
          SYNOVIAL SARCOMA
         </span>
        </p>
        <p class="headingAnchor" id="H1628960170">
         <span class="h2">
          Second-line therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with metastatic synovial sarcoma, anthracyclines with or without
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         are the preferred initial therapy. (See
         <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">
          "Overview of the initial treatment of metastatic soft tissue sarcoma", section on 'Histologies where anthracyclines are preferred'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prior single-agent anthracycline
         </strong>
         – For patients with metastatic synovial sarcoma who progress on a single-agent anthracycline, we suggest second-line therapy with an ifosfamide-based regimen rather than other agents, as synovial sarcoma is highly sensitive to
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         [
         <a href="#rid48">
          48-51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prior anthracyclines and
         </strong>
         <strong>
          ifosfamide
         </strong>
         – For those patients with metastatic synovial sarcoma who progress on anthracyclines and
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         (either in combination or in sequence), we suggest
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         or
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         rather than other systemic agents. Both agents are acceptable options that have improved progression-free survival (PFS) over placebo or best supportive care in randomized trials, although they have not been directly compared. (See
         <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">
          "Overview of the initial treatment of metastatic soft tissue sarcoma", section on 'Ineligible for anthracyclines'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2805791401">
         <span class="h3">
          Pazopanib (synovial sarcoma)
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          Pazopanib
         </a>
         is an option for patients with synovial sarcoma who progress on initial chemotherapy (including but not limited to anthracycline-based chemotherapy). In a randomized, double-blind, placebo-controlled phase III trial (PALETTE), pazopanib demonstrated a non-statistically significant trend towards improved PFS in a subgroup of patients with anthracycline-refractory synovial sarcoma (HR 0.82, 95% CI 0.51-1.32) [
         <a href="#rid6">
          6
         </a>
         ]. Data on pazopanib for the entire study population are discussed separately. (See
         <a class="local">
          'Efficacy and toxicity'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1787311564">
         <span class="h3">
          Trabectedin (synovial sarcoma)
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          Trabectedin
         </a>
         is an option for patients with synovial sarcoma who progress on anthracycline-based chemotherapy. Trabectedin has demonstrated activity as subsequent therapy in translocation-related sarcomas  (
         <a class="graphic graphic_table graphicRef64666" href="/z/d/graphic/64666.html" rel="external">
          table 3
         </a>
         ), including synovial sarcomas [
         <a href="#rid52">
          52,53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7737.html" rel="external">
          "Pathogenetic factors in soft tissue and bone sarcomas", section on 'Chromosomal translocations'
         </a>
         .)
        </p>
        <p>
         In an open-label phase II trial, 76 patients with advanced, translocation-related sarcoma previously treated with an anthracycline (including 18 patients with synovial sarcoma) were randomized to
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         (1.2 mg/m
         <sup>
          2
         </sup>
         over 24 hours on day 1 every 21 days) versus best supportive care [
         <a href="#rid52">
          52
         </a>
         ]. After a median follow-up of approximately nine months, trabectedin improved PFS in the entire study population (5.6 versus 0.9 months, HR 0.07, 95% CI 0.03-0.16), including those with synovial sarcoma (HR 0.14, 95% CI 0.03-0.68). Common grade ≥3 toxicities for trabectedin included nausea (9 percent), decreased appetite (8 percent), febrile neutropenia (11 percent), and increased alanine aminotransferase (47 percent).
        </p>
        <p>
         Data for
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         in other STS histologies such as non-uterine leiomyosarcoma and liposarcoma are discussed separately. (See
         <a class="local">
          'Trabectedin (LMS)'
         </a>
         above and
         <a class="local">
          'Trabectedin (liposarcoma)'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4275571882">
         <span class="h2">
          Later-line therapy (synovial sarcoma)
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          Regorafenib
         </a>
         is a later-line treatment option for metastatic synovial sarcoma. Gemcitabine-based therapy is also an option but has limited efficacy in this population [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2211451330">
         <span class="h3">
          Regorafenib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          Regorafenib
         </a>
         was evaluated in a double-blind, randomized, placebo-controlled trial (REGOSARC) of 182 patients with liposarcoma, LMS, synovial sarcoma, and other types of STS previously treated with an anthracycline [
         <a href="#rid46">
          46
         </a>
         ]. Six patients had previously received
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         . Among patients with synovial sarcoma, regorafenib improved PFS over placebo (6 versus 1 month, HR 0.10, 95% CI 0.30-0.35). The most common adverse events, seen in more than one-third of the regorafenib-treated patients, were asthenia, diarrhea, mucositis, acral erythema, anorexia, and arterial hypertension.
        </p>
        <p class="headingAnchor" id="H3504762584">
         <span class="h1">
          MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
         </span>
        </p>
        <p class="headingAnchor" id="H1835645950">
         <span class="h2">
          Second-line therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with metastatic malignant peripheral nerve sheath tumors (MPNST), options for initial therapies include
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         with or without
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         , and ifosfamide plus
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">
          "Overview of the initial treatment of metastatic soft tissue sarcoma", section on 'Histologies where anthracyclines are preferred'
         </a>
         .)
        </p>
        <p>
         For patients with metastatic MPNST progress on initial therapy with anthracycline and/or ifosfamide-based regimens, we suggest second-line therapy with
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         rather than other systemic therapies. Patients are also encouraged to enroll in clinical trials, where available, since metastatic MPNST has a poor prognosis and effective treatment options are limited.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          Pazopanib
         </a>
         is a relatively well-tolerated agent that improved progression-free survival (PFS) in a placebo-controlled randomized phase III trial (PALETTE) of patients with treatment-refractory STS; although this study presumably included patients with MPNST, the specific number is unreported [
         <a href="#rid6">
          6
         </a>
         ]. Further details of this study are discussed separately. (See
         <a class="local">
          'Pazopanib'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a separate phase II trial of patients with metastatic MPNST previously treated with anthracycline-based therapy, the clinical benefit rate (objective responses and stable disease) was 50 percent. Median PFS and overall survival (OS) were 5 and 11 months, respectively [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Other systemic regimens have minimal efficacy when used as subsequent-line therapy for metastatic MPNST, such as platinum-based therapy;
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         ;
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         ; and single-agent
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3928058161">
         <span class="h1">
          LIPOSARCOMA
         </span>
        </p>
        <p class="headingAnchor" id="H3235725240">
         <span class="h2">
          Second-line therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with metastatic liposarcoma, anthracycline-based regimens are the preferred initial therapy. (See
         <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">
          "Overview of the initial treatment of metastatic soft tissue sarcoma", section on 'Histologies where anthracyclines are preferred'
         </a>
         .)
        </p>
        <p>
         For those with metastatic liposarcoma who progress on anthracyclines-based regimens, we suggest second-line therapy with
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         rather than other systemic agents. Gemcitabine plus docetaxel may be an effective treatment option for patients with metastatic liposarcoma who progress on anthracycline-based therapy, especially those with pleomorphic and well-differentiated/dedifferentiated liposarcoma [
         <a href="#rid23">
          23,24
         </a>
         ]. Single-agent gemcitabine is an appropriate alternative for patients with poor performance status or multiple comorbidities who are unable to tolerate the potential toxicities of gemcitabine-based combination therapy.
        </p>
        <p>
         In a randomized phase II trial of 122 patients with soft tissue sarcoma of various histologies treated with an average of one prior line of therapy, the addition of
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         to
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         improved progression-free survival (PFS) and overall survival (OS) [
         <a href="#rid23">
          23
         </a>
         ]. Among the eight patients with liposarcoma who received gemcitabine plus docetaxel, the best responses were seen among those with the pleomorphic (two partial responses and one with stable disease &lt;24 weeks) and well-differentiated/dedifferentiated (four with stable disease for &lt;24 weeks) subtypes.
        </p>
        <p class="headingAnchor" id="H385923636">
         <span class="h2">
          Later-line therapy (liposarcoma)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to selecting later-line therapy for treatment-refractory liposarcoma is based on the primary histologic subtype of the liposarcoma and patient preference:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dedifferentiated or pleomorphic liposarcoma
         </strong>
         – For most patients with dedifferentiated or pleomorphic liposarcoma who progress on anthracyclines as well as
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         ,
         <a class="drug drug_general" data-topicid="16096" href="/z/d/drug information/16096.html" rel="external">
          eribulin
         </a>
         is an appropriate later-line treatment option. In phase III trials, eribulin conferred an OS benefit over chemotherapy in these histologies, whereas
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         did not. (See
         <a class="local">
          'Eribulin (liposarcoma)'
         </a>
         below and
         <a class="local">
          'Trabectedin (liposarcoma)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For the subset of patients with well-differentiated or dedifferentiated liposarcoma and more indolent disease, a CDK4/6 inhibitor, such as
         <a class="drug drug_general" data-topicid="99759" href="/z/d/drug information/99759.html" rel="external">
          palbociclib
         </a>
         or
         <a class="drug drug_general" data-topicid="115098" href="/z/d/drug information/115098.html" rel="external">
          abemaciclib
         </a>
         , is an alternative to further chemotherapy. (See
         <a class="local">
          'CDK4/6 inhibitors'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myxoid/round cell liposarcoma
         </strong>
         – For patients with myxoid/round cell liposarcoma who progress on anthracyclines and
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         ,
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         is an effective strategy because it targets a unique fusion protein in this translocation-related sarcoma  (
         <a class="graphic graphic_table graphicRef64666" href="/z/d/graphic/64666.html" rel="external">
          table 3
         </a>
         ).
         <a class="drug drug_general" data-topicid="16096" href="/z/d/drug information/16096.html" rel="external">
          Eribulin
         </a>
         is a reasonable alternative but is associated with a lower response rate. (See
         <a class="local">
          'Trabectedin (liposarcoma)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H721015436">
         <span class="h3">
          Eribulin (liposarcoma)
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="16096" href="/z/d/drug information/16096.html" rel="external">
          Eribulin
         </a>
         is one preferred option for most patients with liposarcoma who progress on multiple prior regimens, including anthracycline-based therapy. In a randomized phase III trial, relative to chemotherapy, eribulin improved PFS and OS in patients with liposarcoma of various subtypes (including dedifferentiated, myxoid/round cell, and pleomorphic liposarcoma) but increased toxicity [
         <a href="#rid41">
          41,42
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="16096" href="/z/d/drug information/16096.html" rel="external">
          Eribulin
         </a>
         inhibits microtubules via a mechanism that is distinct from other microtubule-targeting agents, such as taxanes. An initial phase II trial suggested that eribulin was active in a variety of STS histologies, including LMS, adipocytic sarcoma such as liposarcoma, synovial sarcoma, and others [
         <a href="#rid57">
          57
         </a>
         ]. The specific efficacy of eribulin over
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         in advanced liposarcoma was subsequently confirmed in a randomized phase III trial [
         <a href="#rid41">
          41
         </a>
         ]. In this trial, 452 patients with advanced LMS or liposarcoma previously treated with at least two prior systemic regimens (including an anthracycline) were randomly assigned to eribulin (1.4 mg/m
         <sup>
          2
         </sup>
         intravenously on days 1 and 8) or dacarbazine (between 850 and 1200 mg/m
         <sup>
          2
         </sup>
         intravenously on day 1) every 21 days [
         <a href="#rid41">
          41-43
         </a>
         ]. Approximately one-third of patients enrolled had liposarcomas (143 patients). The remaining two-thirds of enrolled patients had LMS (309 patients), of which over one-half had nonuterine disease (57 percent). The use of eribulin in advanced or metastatic LMS of uterine origin is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3188.html" rel="external">
          "Treatment and prognosis of uterine leiomyosarcoma", section on 'Eribulin'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         At a median follow-up of 31 months, relative to
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="16096" href="/z/d/drug information/16096.html" rel="external">
          eribulin
         </a>
         improved overall survival (OS; median 13.5 versus 11.5 months, HR 0.77, 95% CI 0.62-0.95) and demonstrated similar PFS (median 2.6 months in both arms) in the entire study population (LMS and liposarcoma) [
         <a href="#rid41">
          41
         </a>
         ]. Among those with liposarcoma, eribulin improved both OS (15.6 versus 8.4 months, HR 0.51, 95% CI 0.35-0.75) and PFS (median 2.9 versus 1.7 months, HR 0.52, 95% CI 0.35-0.78) [
         <a href="#rid42">
          42
         </a>
         ]. OS benefit was seen across multiple liposarcoma subtypes including dedifferentiated, myxoid/round cell, and pleomorphic liposarcoma [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="16096" href="/z/d/drug information/16096.html" rel="external">
          Eribulin
         </a>
         increased treatment-related toxicity relative to chemotherapy in all patients (67 versus 56 percent), including higher rates of neutropenia (43 versus 24 percent), pyrexia (28 versus 14 percent), peripheral sensory neuropathy (21 versus 4 percent), and alopecia (35 versus 3 percent) [
         <a href="#rid41">
          41,43
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Based on these data,
         <a class="drug drug_general" data-topicid="16096" href="/z/d/drug information/16096.html" rel="external">
          eribulin
         </a>
         was approved by the US Food and Drug Administration (FDA) for patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen [
         <a href="#rid58">
          58
         </a>
         ]; and for similar indications in Canada and Europe. Eribulin is also approved for both leiomyosarcoma and liposarcoma in Japan and the Philippines. (See
         <a class="local">
          'Eribulin (LMS)'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3557263740">
         <span class="h3">
          Trabectedin (liposarcoma)
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          Trabectedin
         </a>
         is one option for patients with liposarcoma who progress on anthracycline-based chemotherapy.
         <a class="drug drug_general" data-topicid="16096" href="/z/d/drug information/16096.html" rel="external">
          Eribulin
         </a>
         is particularly effective for myxoid/round cell liposarcoma, as it improved PFS for this subgroup in a phase III trial [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          Trabectedin
         </a>
         represents a unique form of molecularly targeted therapy in myxoid liposarcoma. Myxoid liposarcoma, a translocation-related sarcoma  (
         <a class="graphic graphic_table graphicRef64666" href="/z/d/graphic/64666.html" rel="external">
          table 3
         </a>
         ), is defined by unique chromosomal translocations that results in the expression of specific fusion oncoproteins. Trabectedin interferes with the ability of these fusion proteins to bind to DNA promoter regions, resulting in antineoplastic effects [
         <a href="#rid59">
          59
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7737.html" rel="external">
          "Pathogenetic factors in soft tissue and bone sarcomas", section on 'Myxoid liposarcomas'
         </a>
         and
         <a class="local">
          'Translocation-related sarcomas'
         </a>
         below.)
        </p>
        <p>
         Based on initial data from observational studies [
         <a href="#rid60">
          60,61
         </a>
         ] and phase II trials [
         <a href="#rid53">
          53,62
         </a>
         ],
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         was evaluated in a randomized, controlled phase III trial (ET743-SAR-3007) of 577 patients with advanced LMS or liposarcoma previously treated with anthracycline-based chemotherapy and at least one additional systemic regimen. Among the subgroup of 154 patients with pretreated liposarcoma, trabectedin resulted in the following, relative to
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         [
         <a href="#rid30">
          30,31
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similar OS but improved PFS (median OS 13.1 versus 12.6 months, HR 1.05, 95% CI 0.69-1.60; median PFS 3.0 versus 1.5 months, HR 0.55, 95% CI 0.34-0.87).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improved PFS in those with myxoid/round cell histology (median 5.6 versus 1.5 months, HR 0.41, 95% CI 0.17-0.98) but not in those with dedifferentiated or pleomorphic histology (median 2.2 versus 1.9 months, HR 0.68, 95% CI 0.37-1.25, and 1.5 versus 1.4 months, HR 0.33, 95% CI 0.07-1.64, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical benefit rates were numerically higher but not statistically significant (28 versus 15 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grade ≥3 toxicities for
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         included neutropenia (37 percent) and transient elevation of transaminases (26 percent for ALT and 13 percent for AST).
        </p>
        <p>
        </p>
        <p>
         Data from this trial for
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         in leiomyosarcoma and the entire study population are discussed separately. (See
         <a class="local">
          'Trabectedin (LMS)'
         </a>
         above.)
        </p>
        <p>
         Based on these data, the FDA approved
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         for patients with advanced leiomyosarcoma and liposarcoma previously treated with an anthracycline-containing chemotherapy regimen [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3752751602">
         <span class="h3">
          CDK4/6 inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         A majority of well-differentiated or dedifferentiated liposarcomas (&gt;90 percent) express amplification of cyclin-dependent kinase (CDK) 4. For such patients, a CDK4/6 inhibitor, such as
         <a class="drug drug_general" data-topicid="99759" href="/z/d/drug information/99759.html" rel="external">
          palbociclib
         </a>
         , is a subsequent-line treatment option with modest efficacy. These agents are a reasonable alternative for patients with more indolent disease who are unable to tolerate or decline chemotherapy.
        </p>
        <p>
         In separate phase II trials of patients with well-differentiated or dedifferentiated liposarcoma,
         <a class="drug drug_general" data-topicid="99759" href="/z/d/drug information/99759.html" rel="external">
          palbociclib
         </a>
         demonstrated a twelve-week PFS of up to 66 percent [
         <a href="#rid63">
          63,64
         </a>
         ], while
         <a class="drug drug_general" data-topicid="115098" href="/z/d/drug information/115098.html" rel="external">
          abemaciclib
         </a>
         demonstrated a twelve-week PFS of 77 percent [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
         The use of other CDK4/6 inhibitors such as
         <a class="drug drug_general" data-topicid="112288" href="/z/d/drug information/112288.html" rel="external">
          ribociclib
         </a>
         or
         <a class="drug drug_general" data-topicid="115098" href="/z/d/drug information/115098.html" rel="external">
          abemaciclib
         </a>
         remains investigational [
         <a href="#rid66">
          66,67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2362852188">
         <span class="h2">
          Agents not used for liposarcoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Agents that are not used to treat advanced or metastatic liposarcoma due to lack of activity include
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         [
         <a href="#rid46">
          46,68
         </a>
         ],
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         [
         <a href="#rid55">
          55,69,70
         </a>
         ], and
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         [
         <a href="#rid71">
          71,72
         </a>
         ].
        </p>
        <p>
         We do not use
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         for adipocytic STS (eg, myxoid/round cell or well differentiated/dedifferentiated liposarcoma) due to limited efficacy, consistent with its lack of regulatory approval for this subtype. In phase II trials of various treatment-refractory STS histologies, pazopanib demonstrated low response rates compared with other STS histologies [
         <a href="#rid55">
          55,69,70
         </a>
         ]. Based on these data, adipocytic histologies such as liposarcoma were excluded from the randomized phase III trial (PALETTE) that evaluated pazopanib in treatment-refractory STS. These data are discussed separately. (See
         <a class="local">
          'Pazopanib'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          Pembrolizumab
         </a>
         has limited activity in dedifferentiated and myxoid/round cell liposarcoma. Although data from a phase II trial (SARC028) suggested that pembrolizumab was active in liposarcoma [
         <a href="#rid71">
          71
         </a>
         ], this was not confirmed in a subsequent expansion cohort [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H716399984">
         <span class="h1">
          UNDIFFERENTIATED AND UNCLASSIFIED SARCOMAS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Undifferentiated and unclassified STS (eg, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and sarcoma not otherwise specified [NOS]) are tumors with aneuploid karyotypes. (See
         <a class="medical medical_review" href="/z/d/html/14259.html" rel="external">
          "Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma", section on 'Most common subtypes'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2005628141">
         <span class="h2">
          Second-line therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with metastatic undifferentiated/unclassified STS, anthracycline-based regimens are the preferred initial therapy. (See
         <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">
          "Overview of the initial treatment of metastatic soft tissue sarcoma", section on 'Histologies where anthracyclines are preferred'
         </a>
         .)
        </p>
        <p>
         For patients who metastatic undifferentiated or unclassified STS who progressed on anthracyclines, we suggest second-line therapy with
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         rather than other systemic agents, as UPS is more responsive to this combination than other histologies. As an example, a randomized phase II trial of 122 patients with metastatic STS of various histologies demonstrated an overall survival (OS) benefit for gemcitabine plus docetaxel over gemcitabine monotherapy [
         <a href="#rid23">
          23
         </a>
         ]. Among the eleven patients with UPS treated with gemcitabine plus docetaxel, partial responses were seen in four patients (36 percent), which was higher than the partial response rate seen in the entire study population (16 percent).
        </p>
        <p class="headingAnchor" id="H124592319">
         <span class="h2">
          Later-line therapy (undifferentiated/unclassified sarcoma)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Later-line treatment options for undifferentiated/unclassified sarcomas include
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         and immune checkpoint inhibitors such as
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         and
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pazopanib
         </strong>
         — In the placebo-controlled phase III trial (PALETTE),
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         improved progression-free survival (PFS) across various non-adipocytic STS histologies previously treated with anthracycline-based regimens. Although this study presumably included patients with undifferentiated/unclassified sarcoma, the specific number is unreported. Further details of this trial are discussed separately. (See
         <a class="local">
          'Efficacy and toxicity'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pembrolizumab
         </strong>
         —
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          Pembrolizumab
         </a>
         is an option for subsequent-line therapy in undifferentiated and unclassified STS, extrapolating from studies of undifferentiated pleomorphic sarcoma (UPS).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In an open-label phase II trial (SARC028),
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         was administered to patients with metastatic STS and bone sarcomas who had received up to three prior lines of systemic therapy. There were 10 patients enrolled to each of four cohorts of STS: undifferentiated pleomorphic sarcoma (UPS), poorly differentiated/dedifferentiated liposarcoma, synovial sarcoma, and LMS [
         <a href="#rid71">
          71,72
         </a>
         ]. In the entire cohort of STS histologies, at median follow-up of 19 months, the objective response rate was 18 percent, and 12-week PFS was 55 percent. Among those with UPS, objective responses were seen in four patients (40 percent) and was subsequent confirmed in an expansion cohort [
         <a href="#rid72">
          72
         </a>
         ]. The other STS histologies (liposarcoma, synovial sarcoma, and LMS) had limited objective responses to pembrolizumab (20 percent or less).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nivolumab
         </strong>
         <strong>
          plus
         </strong>
         <strong>
          ipilimumab
         </strong>
         <strong>
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          Nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         is an option for subsequent-line therapy in undifferentiated and unclassified STS, extrapolating from studies of UPS.
        </p>
        <p>
        </p>
        <p>
         In two noncomparative phase II trials (Alliance A091401), 85 patients with metastatic STS of various histologies previously treated with at least one line of therapy were randomly assigned to either
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         for four doses followed by maintenance nivolumab or single-agent nivolumab [
         <a href="#rid73">
          73
         </a>
         ]. Nivolumab plus ipilimumab demonstrated a higher objective response rate (16 percent; six patients, including those with UPS histology) versus nivolumab (5 percent; two patients). Similar results were seen in an expansion cohort study of A091401. In preliminary results, among the 24 patients with UPS, the objective response rates at six months for nivolumab and ipilimumab was 14 percent [
         <a href="#rid74">
          74
         </a>
         ]. Median duration of response and PFS were approximately 7 and 3 months, respectively.
        </p>
        <p class="headingAnchor" id="H780539460">
         <span class="h1">
          NON-SPECIFIC HISTOLOGIES
         </span>
        </p>
        <p class="headingAnchor" id="H3059811348">
         <span class="h2">
          Pazopanib
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         rather than chemotherapy for patients with other non-specific advanced or metastatic STS histologies who progress on chemotherapy (including but not limited to anthracycline-based regimens) and do not have a histology-specific treatment approach available. In a phase III trial (PALETTE) of patients with anthracycline-resistant metastatic STS, pazopanib improved progression-free survival (PFS) over placebo [
         <a href="#rid6">
          6
         </a>
         ]. Of note, pazopanib is not approved in the United States for the treatment of adipocytic tumors such as liposarcoma, or gastrointestinal stromal tumors (GIST). (See
         <a class="local">
          'Efficacy and toxicity'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2474630960">
         <span class="h3">
          Administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          Pazopanib
         </a>
         is a multitargeted, orally active small molecule inhibitor of several tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor alpha (PDGFRA) and beta (PDGFRB).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pazopanib should be taken either one hour before or two hours after a meal. It should not be administered with proton pump inhibitors or histamine H2 receptor antagonists. Short-acting antacids could be offered in place of these agents, as long as the dosing of antacids and
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         are separated by several hours. The solubility of pazopanib is pH dependent, and an elevated gastric pH (which occurs with gastric acid suppressive agents) may decrease bioavailability [
         <a href="#rid75">
          75,76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients receiving
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         should have close monitoring of liver function tests, given the risk for potentially fatal hepatotoxicity. (See
         <a class="medical medical_review" href="/z/d/html/128144.html" rel="external">
          "Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Molecularly targeted agents", section on 'Pazopanib'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac and non-cardiac toxicities of
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         and other VEGFR tyrosine kinase inhibitors are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2516954325">
         <span class="h3">
          Efficacy and toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Single-agent
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         showed activity in phase II trials that included various treatment-refractory STS subtypes [
         <a href="#rid55">
          55,69
         </a>
         ]. Pazopanib met the primary endpoint for activity in three of the four histology-specific cohorts (leiomyosarcoma [LMS], synovial sarcoma, and other eligible STS types). However, pazopanib demonstrated low response rates in liposarcoma compared with the other STS histologies [
         <a href="#rid69">
          69,70,77
         </a>
         ]. (See
         <a class="local">
          'Agents not used for liposarcoma'
         </a>
         above.)
        </p>
        <p>
         Based on those results,
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         was evaluated in a randomized, double-blind, placebo-controlled phase III study (the PALETTE trial) conducted by the European Organisation for Research and Treatment of Cancer (EORTC). In this study, 369 patients with various histologic STS subtypes (except for adipocytic sarcomas or GIST) whose disease had progressed during or after first-line chemotherapy (including an anthracycline) were randomly assigned to either pazopanib at 800 mg orally daily or placebo [
         <a href="#rid6">
          6
         </a>
         ]. Patients with the most common histologic subtypes were allowed to enroll, including LMS, fibrosarcoma, synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST), vascular STS (such as angiosarcoma), and undifferentiated/unclassified sarcomas (also known as sarcoma not otherwise specified).
        </p>
        <p>
         At median follow-up of 15 months, compared with placebo,
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         improved PFS (median 5 versus 2 months, HR 0.31, 95% CI 0.24-0.40), with consistent benefit across all histologic subtypes. Overall survival (OS) was similar between the two treatment arms (median 13 versus 11 months, HR 0.86, 95% CI 0.67-1.1). Overall response (6 versus 0 percent) and stable disease rates (67 versus 38 percent) were higher for pazopanib versus placebo. The efficacy of pazopanib for those with leiomyosarcoma or synovial sarcoma is discussed separately. (See
         <a class="local">
          'Pazopanib (LMS)'
         </a>
         above and
         <a class="local">
          'Pazopanib (synovial sarcoma)'
         </a>
         above.)
        </p>
        <p>
         Grade ≥3 treatment-related toxicities for
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         included were fatigue (14 percent), hypertension (7 percent), anorexia (6 percent), and diarrhea (5 percent). Pazopanib also increased any grade liver function tests more frequently than placebo for alanine aminotransferase (10 versus 3 percent) and aspartate aminotransferase (8 versus 2 percent). A drop in left ventricular ejection fraction occurred more frequently with pazopanib compared with placebo (7 versus 3 percent); only three cases were symptomatic. Venous thromboembolism was also more common in the pazopanib group (5 versus 2 percent, all grades). In addition, pneumothorax occurred in eight patients in the pazopanib group (3 percent), possibly due to necrosis of pleural lesions. Pazopanib did not improve quality of life metrics in this study compared with placebo [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         Based on these data,
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         was approved in the United States for treatment of patients with advanced STS (but not adipocytic tumors or GIST) who have received prior chemotherapy [
         <a href="#rid78">
          78
         </a>
         ]. Pazopanib also has regulatory approval from the European Medicines Agency (EMA).
        </p>
        <p class="headingAnchor" id="H4175351067">
         <span class="h2">
          Trabectedin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          Trabectedin
         </a>
         is also approved by the European Medicines Agency (EMA) for patients with advanced STS who experience disease progression on
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         and
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         [
         <a href="#rid79">
          79
         </a>
         ]. However, we do not use trabectedin for histologies other than leiomyosarcoma (LMS), liposarcoma, or translocation-related sarcomas. (See
         <a class="local">
          'Trabectedin (LMS)'
         </a>
         above and
         <a class="local">
          'Trabectedin (liposarcoma)'
         </a>
         above and
         <a class="local">
          'Translocation-related sarcomas'
         </a>
         below.)
        </p>
        <p>
         The activity of
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         in STS histologies other than LMS, liposarcoma, and translocation-associated sarcomas was addressed in the phase III T-SAR trial [
         <a href="#rid80">
          80
         </a>
         ]. In this study, 103 patients with advanced STS unresponsive to or intolerant of previous chemotherapy were randomly assigned to trabectedin or best supportive care. Sixty percent of tumors were liposarcoma or LMS, and the remainder were other histotypes. In those with non-liposarcoma/LMS histotypes, trabectedin had no objective tumor responses relative to the liposarcoma/LMS group (0 versus 19 percent) and had similar PFS to those receiving best supportive care (median 1.8 versus 1.5 months). In contrast, for those with liposarcoma/LMS, trabectedin improved PFS relative to best supportive care (median 5.1 versus 1.4 months).
        </p>
        <p class="headingAnchor" id="H3699181822">
         <span class="h2">
          Chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chemotherapy is an option for patients with anthracycline-refractory metastatic soft tissue sarcoma (STS) who progress on or are ineligible for
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         and do not have a histology-specific treatment approach available. Patients should be treated with a chemotherapy regimen not previously received during initial therapy. However, treatment responses for chemotherapy are limited in this setting.
        </p>
        <p>
         For patients with good ECOG performance status  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 4
         </a>
         ) and minimal comorbidities, options include
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         in combination with either
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         [
         <a href="#rid21">
          21,23
         </a>
         ],
         <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">
          vinorelbine
         </a>
         [
         <a href="#rid81">
          81
         </a>
         ], or
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         [
         <a href="#rid82">
          82
         </a>
         ].
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          Ifosfamide
         </a>
         , if not previously received, is also an option, although toxicity makes its use challenging [
         <a href="#rid83">
          83-91
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">
          "Overview of the initial treatment of metastatic soft tissue sarcoma", section on 'Ineligible for anthracyclines'
         </a>
         .)
        </p>
        <p>
         For older adults or patients with significant comorbidities, we offer single-agent chemotherapy to reduce toxicity risk. Options include
         <a class="drug drug_general" data-topicid="10135" href="/z/d/drug information/10135.html" rel="external">
          pegylated liposomal doxorubicin
         </a>
         (if no prior treatment with an anthracycline),
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         [
         <a href="#rid82">
          82,92-94
         </a>
         ],
         <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">
          temozolomide
         </a>
         [
         <a href="#rid44">
          44
         </a>
         ],
         <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">
          vinorelbine
         </a>
         [
         <a href="#rid11">
          11,95
         </a>
         ], and single-agent
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         . All are associated with objective response rates of less than 20 percent, but some patients may have stable, durable treatment responses.
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          Ifosfamide
         </a>
         is not generally used in this population due to significant toxicity.
        </p>
        <p class="headingAnchor" id="H2875801556">
         <span class="h1">
          SPECIAL CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H683175478">
         <span class="h2">
          Translocation-related sarcomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          Trabectedin
         </a>
         is an option for subsequent-line therapy for the group of soft tissue sarcoma (STS) histologies known as translocation-related sarcomas  (
         <a class="graphic graphic_table graphicRef64666" href="/z/d/graphic/64666.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid52">
          52,53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7737.html" rel="external">
          "Pathogenetic factors in soft tissue and bone sarcomas", section on 'Chromosomal translocations'
         </a>
         .)
        </p>
        <p>
         In an open-label phase II trial, 76 patients with advanced, translocation-related, predominantly pretreated sarcoma (including myxoid/round cell liposarcoma and synovial sarcoma) were randomized to
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         (1.2 mg/m
         <sup>
          2
         </sup>
         over 24 hours on day 1 every 21 days) versus best supportive care [
         <a href="#rid52">
          52
         </a>
         ]. After a median follow-up of approximately nine months, trabectedin improved progression-free survival (PFS; 5.6 versus 0.9 months, HR 0.07, 95% CI 0.03-0.16). Common grade ≥3 toxicities for trabectedin included nausea (9 percent), decreased appetite (8 percent), febrile neutropenia (11 percent), and increased alanine aminotransferase (47 percent).
        </p>
        <p>
         The efficacy of
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         for specific translocation-related sarcomas and other STS histologies are discussed separately. (See
         <a class="local">
          'Trabectedin (synovial sarcoma)'
         </a>
         above and
         <a class="local">
          'Trabectedin (liposarcoma)'
         </a>
         above and
         <a class="local">
          'Trabectedin (LMS)'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H555124839">
         <span class="h2">
          Tumors with dMMR, MSI-H, or high levels of TMB
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immune checkpoint inhibitors are an option for patients with metastatic STS of any histologic subtype that harbors either high levels of microsatellite instability (MSI-H)/deficient mismatch repair (dMMR) or high tumor mutational burden (TMB). These molecular alterations are rare in STS.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Deficient mismatch repair and DNA microsatellite instability
         </strong>
         – Approximately 1 to 2 percent of STS tumors are dMMR or express DNA MSI-H [
         <a href="#rid96">
          96
         </a>
         ]  (
         <a class="graphic graphic_figure graphicRef120779" href="/z/d/graphic/120779.html" rel="external">
          figure 1
         </a>
         ). Furthermore, sarcoma is not a cancer that is typically associated with Lynch syndrome. (See
         <a class="medical medical_review" href="/z/d/html/2605.html" rel="external">
          "Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tumor mutational burden
         </strong>
         – High TMB (ie, ≥10 mutations/megabase) is observed at very low frequencies in most STS. High TMB expression is seen in angiosarcomas and pleomorphic dermal sarcomas, although it is rare for the latter to recur after surgery and require systemic therapy. (See
         <a class="local">
          'Angiosarcoma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         Further details on using immune checkpoint inhibitors to treat solid tumors that are dMMR/MSI-H or high TMB is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">
          "Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2359607367">
         <span class="h2">
          <i>
           RET
          </i>
          and other rare gene fusions
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with a treatment-refractory STS harboring a rearranged at transfection (
         <em>
          RET
         </em>
         ) gene fusion and no other actionable molecular alterations,
         <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">
          selpercatinib
         </a>
         is an available treatment option, The use of selpercatinib, a selective RET kinase inhibitor, is based on limited data from two patients with metastatic STS treated in a phase I/II basket trial (LIBRETTO-001) [
         <a href="#rid97">
          97
         </a>
         ]. Selpercatinb is approved by the US Food and Drug Administration (FDA) for adult patients with locally advanced or metastatic solid tumors with
         <em>
          RET
         </em>
         gene fusion that progress on or following prior systemic treatment or who have no satisfactory alternative treatment options [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
         In a similar fashion, the rare patient with metastatic that involves a gene fusion/translocation other than well-recognized entities (eg, dermatofibrosarcoma protuberans with a
         <em>
          PDGFRB
         </em>
         gene fusion, or sarcomas with an
         <em>
          NTRK
         </em>
         gene fusion) can be evaluated for treatment with specific kinase-specific agents, ideally on a clinical trial. (See
         <a class="medical medical_review" href="/z/d/html/89222.html" rel="external">
          "Dermatofibrosarcoma protuberans: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/122713.html" rel="external">
          "TRK fusion-positive cancers and TRK inhibitor therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3253372870">
         <span class="h1">
          INVESTIGATIONAL AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the large information gaps in treatment, we encourage patients with metastatic sarcoma to enroll in clinical trials, where available (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=139327" target="_blank">
          www.clinicaltrials.gov
         </a>
         ). Most clinical trials are conducted at a national and international level at centers of excellence in sarcoma, due to the rarity of the disease.
        </p>
        <p class="headingAnchor" id="H3548623386">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119797.html" rel="external">
          "Society guideline links: Soft tissue sarcoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1205755724">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/17046.html" rel="external">
          "Patient education: Soft tissue sarcoma (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4232314338">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Second and later lines of therapy for metastatic STS
         </strong>
         – Second and later lines of therapy for common metastatic soft tissue sarcomas (STS) histologies will be reviewed here. Enrollment in clinical trials is encouraged, where available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An overview of initial therapy for metastatic STS is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">
          "Overview of the initial treatment of metastatic soft tissue sarcoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Angiosarcomas
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prior anthracyclines
         </strong>
         – For patients with metastatic angiosarcoma who progress on anthracycline-based therapy, we suggest second-line therapy with a taxane (such as
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         (
         <a class="graphic graphic_table graphicRef95037" href="/z/d/graphic/95037.html" rel="external">
          table 1
         </a>
         )) rather than other systemic agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Second-line therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prior taxanes
         </strong>
         – For patients with metastatic angiosarcoma who progress on taxanes, we suggest second-line therapy with an anthracycline-based regimen rather than other systemic agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), extrapolating from studies of anthracyclines as initial therapy that demonstrate similar efficacy to taxanes. (See
         <a class="local">
          'Second-line therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Later-line therapy
         </strong>
         – Later-line options include gemcitabine-based regimens,
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         , or immune checkpoint inhibitors (eg,
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         ) which are particularly effective for cutaneous and head and neck angiosarcomas. (See
         <a class="local">
          'Later-line therapy (angiosarcoma)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Leiomyosarcoma
         </strong>
         – For patients with metastatic leiomyosarcoma (LMS) who progress on initial therapy with anthracycline-based regimens, we suggest second-line therapy with
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         (
         <a class="graphic graphic_table graphicRef58713" href="/z/d/graphic/58713.html" rel="external">
          table 2
         </a>
         ) rather than other gemcitabine-based regimens (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Other gemcitabine-based combination (gemcitabine plus
         <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">
          vinorelbine
         </a>
         , gemcitabine plus
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         ) and single-agent gemcitabine are appropriate alternatives for those unable to tolerate the potential toxicities of combining docetaxel with gemcitabine (See
         <a class="local">
          'Gemcitabine plus docetaxel (LMS)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with metastatic LMS who progress on initial therapy with
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         , we suggest second-line therapy with an anthracycline-based regimen rather than other systemic agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Options include
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         plus
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         and doxorubicin plus
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         . (See
         <a class="local">
          'Anthracycline-based regimens (LMS)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Later-line treatment options (if not previously received) include
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         ,
         <a class="drug drug_general" data-topicid="16096" href="/z/d/drug information/16096.html" rel="external">
          eribulin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         , among other agents. (See
         <a class="local">
          'Later-line therapy (LMS)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Synovial sarcoma
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prior anthracyclines
         </strong>
         – For patients with metastatic synovial sarcoma who progress on a single-agent anthracycline, we suggest second-line therapy with an ifosfamide-based regimen rather than other agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Second-line therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prior anthracyclines and
         </strong>
         <strong>
          ifosfamide
         </strong>
         – For patients with metastatic synovial sarcoma who progress on anthracyclines and
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         (either in combination or in sequence), we suggest
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         or
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         rather than other systemic agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Pazopanib (synovial sarcoma)'
         </a>
         above and
         <a class="local">
          'Trabectedin (synovial sarcoma)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Malignant peripheral nerve sheath tumors
         </strong>
         –
         <strong>
         </strong>
         For patients with metastatic malignant peripheral nerve sheath tumors (MPNST) who progress on initial therapy with anthracyclines and/or ifosfamide-based regimens, we suggest second-line therapy with
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         rather than other systemic therapies (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Malignant peripheral nerve sheath tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Liposarcoma
         </strong>
         –
         <strong>
         </strong>
         For those with metastatic liposarcoma who progress on anthracyclines-based regimens, we suggest second-line therapy with
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         rather than other systemic agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), especially in those with pleomorphic and well-differentiated/dedifferentiated subtypes. (See
         <a class="local">
          'Liposarcoma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our approach to selecting later-line therapy is based on the primary histologic subtype of liposarcoma and patient preference (see
         <a class="local">
          'Later-line therapy (liposarcoma)'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dedifferentiated or pleomorphic liposarcoma
         </strong>
         – For most patients with dedifferentiated or pleomorphic liposarcoma who progress on anthracyclines as well as
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         ,
         <a class="drug drug_general" data-topicid="16096" href="/z/d/drug information/16096.html" rel="external">
          eribulin
         </a>
         is an appropriate later-line treatment option. In phase III trials, eribulin conferred an overall survival benefit over chemotherapy in these histologies, whereas
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         did not. (See
         <a class="local">
          'Eribulin (liposarcoma)'
         </a>
         above and
         <a class="local">
          'Trabectedin (liposarcoma)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For the subset of patients with well-differentiated/dedifferentiated liposarcoma and more indolent disease, a CDK4/6 inhibitor, such as
         <a class="drug drug_general" data-topicid="99759" href="/z/d/drug information/99759.html" rel="external">
          palbociclib
         </a>
         , is an alternative to further chemotherapy. (See
         <a class="local">
          'CDK4/6 inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Myxoid/round cell liposarcoma
         </strong>
         – For patients with myxoid/round cell liposarcoma who progress on anthracyclines and
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         ,
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         is an effective strategy because it targets a unique fusion protein in this translocation-related sarcoma  (
         <a class="graphic graphic_table graphicRef64666" href="/z/d/graphic/64666.html" rel="external">
          table 3
         </a>
         ).
         <a class="drug drug_general" data-topicid="16096" href="/z/d/drug information/16096.html" rel="external">
          Eribulin
         </a>
         is a reasonable alternative but is associated with a lower response rate. (See
         <a class="local">
          'Trabectedin (liposarcoma)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          No role for
         </strong>
         <strong>
          pazopanib
         </strong>
         – We do not use of
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         for adipocytic STS due to limited efficacy and lack of regulatory approval for this subtype. (See
         <a class="local">
          'Agents not used for liposarcoma'
         </a>
         above and
         <a class="local">
          'Pazopanib'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Undifferentiated and unclassified sarcomas
         </strong>
         – For patients with metastatic undifferentiated and unclassified STS (eg, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and sarcoma not otherwise specified [NOS]) who progress on anthracycline-based chemotherapy, we suggest second-line therapy with
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         rather than other systemic agents. (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Undifferentiated and unclassified sarcomas'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Later-line treatment options include
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         ,
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         , and
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         . (See
         <a class="local">
          'Later-line therapy (undifferentiated/unclassified sarcoma)'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Verweij J, Lee SM, Ruka W, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 2000; 18:2081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008; 26:5269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 2005; 104:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Italiano A, Cioffi A, Penel N, et al. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer 2012; 118:3330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Angelo SP, Munhoz RR, Kuk D, et al. Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma. Oncology 2015; 89:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379:1879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thiebaud JA, Ravi V, Litwin S, et al. OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma. Cancer 2022; 128:3516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones RL, Ravi V, Brohl AS, et al. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol 2022; 8:740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Florou V, Rosenberg AE, Wieder E, et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother Cancer 2019; 7:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner MJ, Othus M, Patel SP, et al. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). J Immunother Cancer 2021; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson SE, Keohan ML, D'Adamo DR, Maki RG. A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas. Sarcoma 2006; 2006:15947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agulnik M, Schulte B, Robinson S, et al. An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma. Eur J Cancer 2021; 154:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27:3133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Mehren M, Rankin C, Goldblum JR, et al. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer 2012; 118:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009; 27:3154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005; 23:7135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 2013; 24:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ray-Coquard IL, Domont J, Tresch-Bruneel E, et al. Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. J Clin Oncol 2015; 33:2797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bay JO, Ray-Coquard I, Fayette J, et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 2006; 119:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Somaiah N, Van Tine BA, Wahlquist AE, et al. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer 2021; 127:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20:2824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leu KM, Ostruszka LJ, Shewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004; 22:1706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007; 25:2755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi Y, Yun MS, Lim SH, et al. Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study. Cancer Res Treat 2018; 50:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist 2012; 17:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrero AB, Martín-Castellanos C, Marco E, et al. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006; 66:8155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paz-Ares L, López-Pousa A, Poveda A, et al. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs 2012; 30:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jordan K, Jahn F, Jordan B, et al. Trabectedin: Supportive care strategies and safety profile. Crit Rev Oncol Hematol 2015; 94:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27:4188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demetri GD, von Mehren M, Jones RL, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol 2016; 34:786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel S, von Mehren M, Reed DR, et al. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer 2019; 125:2610.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22:890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004; 22:1480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005; 23:5484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grosso F, D'Ambrosio L, Zucchetti M, et al. Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group. Cancer 2020; 126:4726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delaloge S, Yovine A, Taamma A, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. J Clin Oncol 2001; 19:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blay JY, Italiano A, Ray-Coquard I, et al. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer 2013; 13:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samuels BL, Chawla S, Patel S, et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol 2013; 24:1703.
          </a>
         </li>
         <li class="breakAll">
          Trabectedin -- United States Food and Drug Administration Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207953s005lbl.pdf (Accessed on October 23, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016; 387:1629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demetri GD, Schöffski P, Grignani G, et al. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. J Clin Oncol 2017; 35:3433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blay JY, Schöffski P, Bauer S, et al. Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. Br J Cancer 2019; 120:1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia del Muro X, Lopez-Pousa A, Martin J, et al. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer 2005; 104:1706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talbot SM, Keohan ML, Hesdorffer M, et al. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer 2003; 98:1942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mir O, Brodowicz T, Italiano A, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2016; 17:1732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmoll HJ, Lindner LH, Reichardt P, et al. Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. JAMA Oncol 2021; 7:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 1994; 73:2506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spillane AJ, A'Hern R, Judson IR, et al. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol 2000; 18:3794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vlenterie M, Litière S, Rizzo E, et al. Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity. Eur J Cancer 2016; 58:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goy BW, Syed S, Padmanabhan A, et al. The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience. Radiother Oncol 2021; 165:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawai A, Araki N, Sugiura H, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol 2015; 16:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takahashi M, Takahashi S, Araki N, et al. Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies. Oncologist 2017; 22:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pender A, Davis EJ, Chauhan D, et al. Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. Med Oncol 2018; 35:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishida Y, Urakawa H, Nakayama R, et al. Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors. Int J Cancer 2021; 148:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobczuk P, Teterycz P, Czarnecka AM, et al. Systemic Treatment for Advanced and Metastatic Malignant Peripheral Nerve Sheath Tumors-A Sarcoma Reference Center Experience. J Clin Med 2020; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schöffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 2011; 12:1045.
          </a>
         </li>
         <li class="breakAll">
          Eribulin: United States Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201532s015lbl.pdf (Accessed on October 26, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groso F, Forni C, Frapolli R, et al. Sensitivity of myxoid round-cell liposarcoma to trabectidin may be related to a direct effect on the fusion transcript (abstract). J Clin Oncol 2007; 25:545s.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007; 8:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009; 20:1439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Cesne A, Blay JY, Domont J, et al. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. Lancet Oncol 2015; 16:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickson MA, Schwartz GK, Keohan ML, et al. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial. JAMA Oncol 2016; 2:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 2013; 31:2024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrew Dickson M, Koff A, D'Angelo SF, et al. Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma. J Clin Oncol 2019; 15S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Infante JR, Cassier PA, Gerecitano JF, et al. A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas. Clin Cancer Res 2016; 22:5696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bautista F, Paoletti X, Rubino J, et al. Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial. J Clin Oncol 2021; 39:3546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riedel RF, Ballman KV, Lu Y, et al. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. Oncologist 2020; 25:e1655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27:3126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samuels BL, Chawla SP, Somaiah N, et al. Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Cancer 2017; 123:4640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 2017; 18:1493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgess MA, Bolejack V, Schuetze S, et al. Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts. J Clin Oncol 2019; 37S; 15S (Abstract #11015).
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Angelo SP, Mahoney MR, Van Tine BA, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 2018; 19:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen JL, Mahoney MR, George S, et al. A multicenter phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts. J Clin Oncol 2020; 38:11511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Gion P, Kanefendt F, Lindauer A, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet 2011; 50:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mir O, Touati N, Lia M, et al. Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials. Clin Cancer Res 2019; 25:1479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coens C, van der Graaf WT, Blay JY, et al. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072). Cancer 2015; 121:2933.
          </a>
         </li>
         <li class="breakAll">
          Pazopanib: United States Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022465s029lbl.pdf (Accessed on October 17, 2022).
         </li>
         <li class="breakAll">
          Yondelis - European Medicines Agency (EMA) -- https://www.ema.europa.eu/en/medicines/human/EPAR/yondelis (Accessed on October 23, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Cesne A, Blay JY, Cupissol D, et al. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. Ann Oncol 2021; 32:1034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dileo P, Morgan JA, Zahrieh D, et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer 2007; 109:1863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García-Del-Muro X, López-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011; 29:2528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J Clin Oncol 1997; 15:2378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keohan ML, Taub RN. Chemotherapy for advanced sarcoma: therapeutic decisions and modalities. Semin Oncol 1997; 24:572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bramwell VH, Mouridsen HT, Santoro A, et al. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 1993; 31 Suppl 2:S180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antman KH, Ryan L, Elias A, et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989; 7:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen OS, Judson I, van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2000; 36:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cerny T, Leyvraz S, von Briel T, et al. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1999; 10:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buesa JM, López-Pousa A, Martín J, et al. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS). Ann Oncol 1998; 9:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Oosterom AT, Mouridsen HT, Nielsen OS, et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 2002; 38:2397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007; 25:3144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gottlieb JA, Benjamin RS, Baker LH, et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep 1976; 60:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buesa JM, Mouridsen HT, van Oosterom AT, et al. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. Ann Oncol 1991; 2:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zucali PA, Bertuzzi A, Parra HJ, et al. The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas. Invest New Drugs 2008; 26:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casanova M, Ferrari A, Spreafico F, et al. Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer 2002; 94:3263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonneville R, Krook MA, Kautto EA, et al. Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol 2017; 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol 2022; 23:1261.
          </a>
         </li>
         <li class="breakAll">
          Selpercatinib: US Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf (Accessed on October 13, 2022).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 139327 Version 6.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10811673" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18809609" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15948172" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22045619" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26043723" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22595799" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35942596" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35357396" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31395100" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34380663" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17496991" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34284255" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19451436" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21751200" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19451429" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16192597" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22910841" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26215950" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16496406" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33231866" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12065559" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15117993" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17602081" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28361521" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22907974" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16912194" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20960029" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25794812" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Trabectedin: Supportive care strategies and safety profile.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19652065" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26371143" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31173362" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14990645" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15659504" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15084621" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16110008" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32749681" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11230465" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23388156" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23385197" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23385197" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26874885" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28854066" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31065111" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16134177" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14584078" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27751846" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33355646" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8174046" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Synovial sarcoma. Uniform response of metastases to high dose ifosfamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11078492" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26968015" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34758339" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25795406" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28526720" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30128716" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32638374" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33003503" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Systemic Treatment for Advanced and Metastatic Malignant Peripheral Nerve Sheath Tumors-A Sarcoma Reference Center Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21937277" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21937277" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Sensitivity of myxoid round-cell liposarcoma to trabectidin may be related to a direct effect on the fusion transcript (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17586092" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19465423" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25680558" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27124835" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23569312" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27542767" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34347542" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32701199" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19451427" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28832986" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28988646" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29370992" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A multicenter phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21827214" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30765389" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26033286" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26033286" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26033286" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33932507" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17385194" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21606430" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9196153" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9344324" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Chemotherapy for advanced sarcoma: therapeutic decisions and modalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8453694" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2491883" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10741296" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10572607" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9789610" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12460784" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17634494" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/769974" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Role of DTIC (NSC-45388) in the chemotherapy of sarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1868027" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17898927" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12115359" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29850653" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Landscape of Microsatellite Instability Across 39 Cancer Types.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36108661" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
